U.S. National Institutes Of Health, India's Cadila Healthcare Join Forces To Develop A New HPV Vaccine
This article was originally published in PharmAsia News
Executive Summary
SINGAPORE - India's Zydus Cadila has joined hands with the U.S.-based National Institutes of Health to develop a new prophylactic vaccine against human papilloma virus - known to be a major cause of cervical cancer
You may also be interested in...
Sanofi Beats GSK To Buy Merieux Alliance's Stake In India's Shantha Biotech; Move Aimed At Stronger Vaccines Business In Emerging Markets
MUMBAI - In a takeover battle that lasted several months, drug maker Sanofi-Aventis emerged winner beating global rival GlaxoSmithKline among others to lap up a majority equity stake in India's Shantha Biotechnics from fellow French pharmaceutical firm Merieux Alliance. Shantha Biotechnics was valued at €550 million ($750 million) on expected sales of €90 million for the current financial year
Merck Launches Gardasil In India At Half U.S. Price
MUMBAI - Merck's India affiliate MSD Pharmaceuticals has launched blockbuster cervical cancer vaccine Gardasil in India at $170 (Rs 8,400) per three-dose regimen, nearly half of its U.S. price of $350
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).